PPT-Implications of cannabis international regulation and its impact on medicinal use

Dra Leticia Cuñetti June 2018 I declare that I have no conflicts of interest to make this presentation Dra Leticia Cuñetti Delmonte June 2018 Chronic pain is a major therapeutic problem in patients with kidney transplant due to the nephrotoxicity of NSAIDs. Cannabis contains a number of active substances like dronabinol THC and cannabidiol CBD THC is mainly responsible for the e64256ects of cannabis but others like CBD may also in64258uence the e64256ectiveness of the drug The chemical composition of Cannabis. Shelly Van Winkle . RN. Member, American Cannabis Nurses Association. April 8, . 2015. Shelly Van Winkle, RN. 2. With Eli, Changes. 3. Endocannabinoid. System, or ECS. 4. 5. 6. Cannadinoids. Spinal Stenosis, Pain and Medicinal Marijuana. PSP Managing Pain Cases. Explain the physician’s role in the MMPR (Marijuana for Medical Purposes Regulations).. Describe a professional and responsible way to excuse yourself from that role if you are uncomfortable.. Professor Jennifer H. Martin . MBChB. , FRACP, PhD. Chair, Clinical Pharmacology. Uni. of Newcastle, Australia. Overview. Need for evidence . Where there is evidence. Challenges of cannabis research . Presented by: Candice Beathard, PhD. December 15, 2015 . Background: History of Cannabis as Medicine . Dates back to 2727B.C. in China. 1. In U.S…. 1850: cannabis tinctures patented. 2. . 1963: chemical structure of cannabis identified. Cannabis. Shelly Van Winkle . RN. Member, American Cannabis Nurses Association. April 8, . 2015. Shelly Van Winkle, RN. 2. With Eli, Changes. 3. Endocannabinoid. System, or ECS. 4. 5. 6. Cannadinoids. he . Report of the Task Force on Cannabis Legalization and Regulation. For. Emerging Practices and Legal Context for Prescription Drugs and Marijuana in VAW Shelters. Susan Boyd, PhD, University of Victoria. Victoria. Dr. Daniel Perkins. Manager Research Strategy and Policy. Office of Medicinal Cannabis. Department of Health and Human Services Victoria. Cannabis regulatory framework. Victorian reform. December . Dr. Robert Strang, CMOH. Nova Scotia Department of Health and Wellness . Cannabis . use, lifetime and past year, . by . province, 2013. . Health Canada (2014). Last 12 month use of cannabis, by province, grades . Dra. Leticia Cuñetti. June 2018. . I declare that I have no conflicts of interest to make this presentation.. . . Dra. Leticia Cuñetti . Delmonte. June 2018. Chronic pain is a major therapeutic problem in patients with kidney transplant due to the nephrotoxicity of NSAIDs. “Medicinal Marijuana” is being used as a smokescreen for allowing recreational dope Politicians are considering the issue of medicinal marijuana e Labour-led government is focusing on t Presentation to Parliament . Cannabis for Private Purposes Bill . CTAA general framework. The CTAA recognizes the voices of Jeremy Upton and Gareth Prince and would like to state our agreement with them regarding the aspects they have raised on the privacy of cannabis bill.. Learning Objectives. Summarise regulatory changes and other issues that need to be considered for the legal use and supply of medicinal cannabis . Discuss the Commonwealth and state specific requirements to prescribe and dispense medicinal cannabis in Australia. world. Tania Ramírez. Map of countries in which medicinal cannabis is available. Medicinal cannabis . regulated. Argentina, Australia, Brazil, Canada, Chile, Colombia, Croatia, Czech Republic, Finland, France, Germany, Greece, Israel, Italy,...